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Abstract
The characteristics of rheumatoid arthritis (RA) pathology
include the infiltration of inflammatory leukocytes, the
proliferation of synovial cells, and the presence of extensive
angiogenesis, referred to as rheumatoid pannus. Fas ligand is
critical to the homeostatic regulation of the immune response,
but its role in the angiogenic process of RA remains to be
defined. In this study, we investigated whether soluble Fas
ligand (sFasL) induces synoviocyte apoptosis and regulates
angiogenesis of endothelial cells in RA. The levels of sFasL were
elevated in the synovial fluids of RA patients when compared to
those of osteoarthritis (OA) patients, and they correlated
inversely with vascular endothelial growth factor165 (VEGF165)
concentrations. sFasL, ranging from 10 to 100 ng/ml, induced
the apoptosis of RA fibroblast-like synoviocytes (FLS) in vitro,
and thereby decreased VEGF165 production. In addition, sFasL
inhibited VEGF165-induced migration and chemotaxis of
endothelial cells to basal levels in a manner independent of the
Fas-mediated cell death. sFasL dose-dependently suppressed
the VEGF165-stimulated increase in pAkt expression in
endothelial cells, which might be associated with its anti-
migratory effect on endothelial cells. Moreover, sFasL strongly
inhibited neovascularization in the Matrigel plug in vivo. Our data
suggest that sFasL shows anti-angiogenic activity within RA
joints not only by inducing apoptosis of VEGF165-producing
cells but also by blocking VEGF165-induced migration of
endothelial cells, independent of Fas-mediated apoptosis.
Introduction
Rheumatoid arthritis (RA) is a multi-systemic autoimmune dis-
ease of unknown etiology that is characterized by hyperplastic
synovial membrane capable of destroying adjacent articular
cartilage and bone [1,2]. The pathology of RA synovial mem-
brane includes infiltration of inflammatory leukocytes, prolifer-
ation of synovial cells and extensive angiogenesis, which is
collectively referred to as the rheumatoid pannus [2-4]. A crit-
ical phenomenon occurring in the early stages of synovial
inflammation is angiogenesis [4,5], which commences with
the activation of endothelial cells by a variety of stimuli, includ-
ing pro-inflammatory cytokines and growth factors such as
vascular endothelial growth factor (VEGF). The affected
endothelial cells (ECs) then begin to digest the basement
membrane, proliferate, migrate and eventually differentiate to
form a tubular structure [6].
Fas (also known as CD95) was initially discovered as a cell
surface molecule that efficiently triggers death signals when
bound to its ligand, Fas ligand (FasL) [7,8]. Fas is ubiquitously
expressed, whereas FasL is principally expressed on activated
T cells [7], natural killer cells [9], tumor cells [10], and in
immune privileged sites such as the eye [11]. The Fas-FasL
interaction plays a pivotal role in activation-induced cell death
of T lymphocytes [12], and is responsible for the cytotoxicity of
T lymphocytes [13,14] and natural killer cells [9]. Conse-
quently, Fas and FasL are crucial components of lymphocyte
homeostasis. In addition to the homeostatic regulation of the
immune system, Fas and FasL are involved in tumor
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surveillance [15,16]. Moreover, Fas and FasL are thought to
inhibit angiogenesis by inducing apoptosis of either ECs or
leukocytes that provide angiogenic growth factors [17-20],
although one study reported an increase in angiogenesis by
Fas and FasL [21]. Similar to tumor necrosis factor (TNF)-α,
FasL is cleaved from the cell surface by a metalloproteinase
[22]. The released form of FasL, soluble FasL (sFasL), was
originally thought to induce apoptosis in a manner similar to
membrane-associated FasL (mFasL) [23]. However, there
have been many subsequent reports upholding the differ-
ences between sFasL and mFasL regarding apoptosis induc-
tion [24,25]. Despite the numerous studies on the role of Fas
and FasL in immune homeostasis, the effect of sFasL on the
angiogenic process of RA remains to be determined.
In this study, we tested whether sFasL can regulate angiogen-
esis and apoptosis of rheumatoid synoviocytes. We demon-
strate here that sFasL potently decreased VEGF165
production by RA fibroblast-like synoviocytes (FLSs) by induc-
ing apoptosis in vitro. In addition, sFasL effectively inhibited
VEGF165-induced migration and chemotaxis of ECs, although
it did not affect tube formation by ECs. The effect of sFasL on
ECs was not due to Fas-mediated cell death, since sFasL did
not change either spontaneous or VEGF165-stimulated EC
proliferation or survival. Moreover, sFasL strongly inhibited
neovascularization in the Matrigel plug in vivo. Taken together,
sFasL inhibits angiogenesis within RA synovium not only by
inducing apoptosis of VEGF165-producing cells such as FLSs,
but also by blocking VEGF165-induced migration of ECs, inde-
pendent of Fas-mediated apoptosis.
Materials and methods
Culture of RA synoviocytes and collection of synovial 
fluids
The RA FLSs were prepared from the synovial tissues of ten
RA patients that were undergoing total joint replacement sur-
gery, as described previously [26]. The mean age of the RA
patients (9 females and 1 male) was 48.3 years. Eight patients
had a positive rheumatoid factor. Osteoarthritis (OA) FLSs,
isolated from 5 female OA patients (mean age 66.2 years),
were used as a control. Synovial tissues were minced into 2 to
3 mm pieces, and treated for 4 hours with 4 mg/ml of type I
collagenase (Worthington Biochemical, Freehold, NJ, USA) in
DMEM at 37°C in a 5% CO2 atmosphere. Dissociated cells
were then resuspended in DMEM, supplemented with 10%
FCS, 2 mM glutamine, penicillin and streptomycin, and then
plated in 75 cm2 flasks. After overnight culturing, the non-
adherent cells were removed and adherent cells cultivated in
DMEM plus 10% FCS. Cultures were kept at 37°C in a 5%
CO2 atmosphere, and the medium was replaced every 3 days.
At confluence, the cells were passed by diluting 1:3 with fresh
medium and re-cultured until used. Synoviocytes, from pas-
sages 4 through 8, were used for each experiment. The FLSs
were washed in DMEM and then incubated for an additional
24 hours in serum-free DMEM supplemented with insulin-
transferrin-selenium A (ITSA; Life Technologies, Grand Island,
NY, USA). The cells (3 × 104 cells/well) were seeded in tripli-
cate into 24-well plates (Nunc, Roskilde, Denmark) in serum-
free DMEM (supplemented with ITSA) without or with trans-
forming growth factor (TGF)-β (PeproTech, London, UK) in the
presence of sFasL (10 to 100 ng/ml; MBL, Nagoya, Japan).
After the indicated hours of incubation, cell viability was tested
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay, and the cell-free media were collected to
measure VEGF165 concentration in the culture supernatants.
Synovial fluid was obtained with informed consent from RA
and OA patients with joint effusion, and stored at -20°C in a
refrigerator. All samples were obtained according to the guide-
lines approved by the Ethics Committee of the Catholic Uni-
versity of Korea.
ELISA for sFas and VEGF165
The amount of sFasL and VEGF165 was measured by ELISA,
as previously described [27]. Recombinant human sFasL and
VEGF165 (R & D, Minneapolis, MN, USA) were used as a cali-
bration standard. A standard curve was drawn by plotting the
optical density versus the log of the concentration of sFas and
VEGF165.
Isolation and culture of endothelial cells
The ECs were isolated from normal-term umbilical cord vein by
collagenase digestion, and then grown to confluence in 75
cm2 flasks containing M199 medium (Life Technologies) sup-
plemented with 20% FCS, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 2 mM L-glutamine. Cultures were kept at
37°C in a CO2 incubator, and the medium was changed every
2 to 3 days until confluence was reached. ECs were passed
with 0.2% collagenase and 0.02% EDTA (Life Technologies);
cells from passages 2 to 3 were used in this study.
Determination of endothelial cell proliferation and 
viability
The proliferation and survival of ECs were assessed by [3H]-
thymidine incorporation assay and MTT assay, respectively.
Briefly, ECs were incubated for 24 hours in DMEM supple-
mented with 1% FCS. The medium was replaced with fresh
DMEM/ITSA supplemented with 1% FCS, and the cells were
incubated without or with 10 ng/ml of VEGF165 in the pres-
ence of sFasL (1 to 100 ng/ml) for 24 hours. For the determi-
nation of the proliferation rate of ECs, 1 μCi of [3H]-thymidine
was added to each of the wells prior to the final 6 hours of cul-
turing, and the incorporated radioactivity was counted with a
scintillation counter.
Wounding migration and tube formation assay
The wounding migration and tube formation activity of ECs
were measured as described previously [28]. In brief, ECs
plated at confluence on 60 mm culture dishes were wounded
with pipette tips, and then treated with VEGF165 (20 ng/ml) in
M199 medium, supplemented with 1% FCS and 1 mM ofAvailable online http://arthritis-research.com/content/9/2/R42
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thymidine. After 12 hours of incubation, migration was quanti-
fied by counting the cells that had moved beyond the refer-
ence line. For the tube formation assay, ECs were seeded on
a layer of previously polymerized Matrigel (BD Biosciences,
San Jose, CA, USA) with VEGF165 (20 ng/ml). After 18 hours
of incubation, the cell morphology was visualized via phase-
contrast microscopy and photographed. The degree of tube
formation was quantified by measuring the length of tubes in 5
randomly chosen low-power fields (×40) from each well using
image-Pro Plus v4.5 (Media Cybernetics, San Diego, CA,
USA).
Chemotaxis assay of endothelial cells
The chemotactic migration of ECs was assayed using a Tran-
swell chamber with 6.5 mm diameter polycarbonate filters (8
μm pore size). In brief, the filter's lower surface was coated
with 10 μg of gelatin. VEGF165 (10 ng/ml), which was pre-
pared in M199 medium containing 1% FCS, was placed in the
lower wells. The ECs that were incubated in M199 with 1%
FCS for 6 hours or overnight were trypsinized and suspended
at a final concentration of 1 × 106 cells/ml in M199 containing
1% FCS. Various concentrations of sFasL or soluble CD40
ligand (sCD40L; R & D) were added to the upper wells with
100 μl of cell suspensions. The chamber was incubated at
37°C for 4 hours. The cells were fixed and stained with hema-
toxylin and eosin. Non-migrating cells on the filter's upper sur-
face were removed by wiping with a cotton swab. Chemotaxis
was quantified by counting the cells that migrated to the lower
side of the filter by optical microscopy at ×200 magnification.
Eight random fields were counted for each assay. Each sam-
ple was assayed in duplicate.
Western blot analysis for phospho-Akt and phospho-
ERK
ECs were incubated for 24 hours in DMEM with 1% FCS, and
then VEGF165 (20 ng/ml) plus various concentrations of sFasL
(1 to 50 ng/ml) were added to the cells for the indicated times.
The treated ECs were then washed twice in PBS, dissolved in
sample buffer (50 mM Tris-HCl, 100 mM NaCl, 0.1% SDS,
1% NP-40, 50 mM NaF, 1 mM Na3VO4, 1 μg/ml aprotinin, 1
μg/ml pepstatin, and 1 μg/ml leupeptin), boiled, separated via
SDS-PAGE, and transferred to nitrocellulose membranes.
After immunoblot analysis with anti-phospho-ERK1/2
(Thr202/Tyr204) or anti-phospho-Akt (Ser473), the mem-
branes were stripped and re-incubated with β-actin antibody
in order to detect total protein amounts.
Mouse Matrigel plug assay
Matrigel (500 μl) containing VEGF165 (500 ng/ml) and heparin
(9 U/ml) were injected subcutaneously with or without sFasL
(100 ng/ml) into the abdomen of C57BL/6 mice (7 weeks of
age), as described previously [28]. After 14 days, the skins of
the mice were pulled back to expose the Matrigel plugs, which
remained intact. After noting and photographing any quantita-
tive differences, hemoglobin levels were measured by the
Figure 1
Inverse correlation between soluble Fas ligand (sFasL) and vascular  endothelial growth factor (VEGF) levels in patients with rheumatoid  arthritis (RA) Inverse correlation between soluble Fas ligand (sFasL) and vascular 
endothelial growth factor (VEGF) levels in patients with rheumatoid 
arthritis (RA). (a) Concentrations of sFasL in synovial fluid of patients 
with RA (n = 29) and osteoarthritis (OA, n = 30). (b) Correlation of 
VEGF165 concentration with sFasL level in the sera of patients with RA. 
(c) Correlation between VEGF165 and sFasL levels in the synovial fluid 
of patients with RA.Arthritis Research & Therapy    Vol 9 No 2    Kim et al.
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Drabkin method, using a Drabkin reagent kit 525 (Sigma, St.
Louis, MO, USA). The hemoglobin concentration was calcu-
lated from the parallel assay of a known amount of hemoglobin.
The Matrigel plugs were fixed in 4% formalin, embedded with
paraffin, and stained using hematoxylin and eosin.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD).
Comparisons of the numerical data between groups were per-
formed by paired or unpaired Mann-Whitney U-test. P values
less than 0.05 are considered statistically significant.
Results
sFasL and VEGF165 levels correlate inversely in patients 
with RA
Using ELISA, sFasL was detected in synovial fluids from RA
patients (n = 29) and OA patients (n = 30) (Figure 1a). As with
another reported study [27], the concentration of sFasL in the
synovial fluid of RA patients was significantly higher than that
of OA patients (mean levels of sFasL: 753 ± 335 versus 474
± 401 pg/ml, P = 0.005). It has been reported that there is an
inverse correlation between apoptotic (FasL, caspase-3) and
angiogenic (VEGF, microvessel density) factors in squamous
cell lung carcinomas [19]. To determine the relationship
between sFasL and VEGF165, the serum and synovial fluids of
RA patients were simultaneously measured for sFasL and
VEGF165 by ELISA. As reported earlier [29], the VEGF165 level
was significantly higher in synovial fluids of RA patients than
those of OA patients (mean levels of VEGF165: 823 ± 615 ver-
sus 230 ± 131 pg/ml, P = 0.015). In RA patients, there were
strong negative correlations between VEGF165 and sFasL lev-
els in the sera (r = -0.591, P = 0.001) and synovial fluids (r =
-0.579, P = 0.001) (Figure 1b,c). However, sFasL levels in OA
synovial fluids did not show any correlation with VEGF165 con-
centrations (data not shown).
sFasL decreases VEGF165 production by synovial 
fibroblasts via apoptosis induction
It is well known that FLSs are the major site of VEGF165 pro-
duction in RA joints [30]. Based on the finding of an inverse
correlation between sFasL and VEGF165 levels in RA synovial
fluids, we attempted to determine the effects of sFasL on
VEGF165 production by FLSs in vitro. For this, RA FLSs were
cultured in the presence of sFasL for 24 hours either with
medium alone or with the supplementary addition of TGF-β
(10 ng/ml), since TGF-β has been described to strongly
induce VEGF165 [31,32]. As seen in Figure 2a, sFasL, ranging
from 10 to 100 ng/ml, dose-dependently decreased both
spontaneous and TGF-β-stimulated VEGF165 production by
RA FLSs cultured without FCS. The sFasL-induced decrease
in VEGF165 production appears to be mediated by cell death,
because similar concentrations of sFasL decreased FLS sur-
vival to 55% of the basal level, as determined by MTT assay
(Figure 2b). The sFasL-mediated cell death was partially
blocked by co-treating RA FLSs (n = 7) with 1% FCS (Figure
2b). OA FLSs (n = 5) were resistant to sFasL-induced cell
Figure 2
Effect of soluble Fas ligand (sFasL) on vascular endothelial growth factor (VEGF)165 production by synovial fibroblasts Effect of soluble Fas ligand (sFasL) on vascular endothelial growth factor (VEGF)165 production by synovial fibroblasts. (a) Fibroblast-like synovio-
cytes (FLSs) were cultured in triplicate for 24 hours with medium alone and transforming growth factor (TGF)-β (10 ng/ml) in the presence of various 
concentrations of sFasL (10 to 100 ng/ml). The amount of VEGF165 in the culture supernatants was determined by ELISA. Data are the mean ± 
standard deviation (SD) of three independent experiments in triplicate. *P < 0.05; †P < 0.01 versus the cells stimulated with medium alone or TGF-
β in the absence of sFasL. (b) The rheumatoid arthritis FLSs (RAFLS; n = 7) or osteoarthritis FLSs (OAFLS; n = 5) were treated with increasing con-
centrations of sFasL (1 to 100 ng/ml) in the absence or presence of 1% FCS for 24 hours. The viability of FLS was determined by the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data are expressed as the mean ± SD. *P < 0.01 versus OAFLS.Available online http://arthritis-research.com/content/9/2/R42
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death, indicating that the apoptotic action of sFasL may be
specific to RA FLSs. These results, together with the data pre-
sented in Figure 1, suggest that sFasL may indirectly partici-
pate in anti-angiogenesis by eliminating VEGF165-producing
cells in RA joints, but not in OA joints.
Effect of sFasL on angiogenesis of ECs in vitro
To investigate the effect of sFasL on the survival and prolifera-
tion of ECs, these cells were cultured with various concentra-
tions of sFasL (1 to 100 ng/ml) in the absence or presence of
1% FCS. As expected, EC death was induced dose-depend-
ently by treating the cells with sFasL in the absence of FCS
(data not shown). However, when 1% FCS was added to the
EC culture, sFasL failed to affect EC survival and proliferation,
which were assessed by MTT assay and [3H]-thymidine incor-
poration assay, respectively (Figure 3a,b). The VEGF165-
induced formation of tube-like structures by ECs was also not
altered by the addition of sFasL (10 to 100 ng/ml; Figure 3c).
In angiogenesis, ECs migrate in response to several chemo-
tactic factors [6]. Therefore, we attempted to elucidate
whether sFasL affects VEGF165-induced EC migration and
chemotaxis. As shown in Figure 4a, sFasL suppressed
VEGF165-induced wounding migration of ECs. Moreover,
sFasL strongly inhibited VEGF165-induced chemotaxis of ECs,
determined by using a Transwell chamber (Figure 4b),
whereas sCD40L (0.1 to 100 ng/ml) did not affect it. These
data suggest that sFasL inhibits angiogenesis by blocking
migration and chemotaxis of ECs, independent of Fas-medi-
ated cell death.
sFasL inhibits VEGF165-induced upregulation of 
phospho-Akt expression
VEGF165 exerts its biological effects by binding to its recep-
tors, which include fms-like tyrosine kinase (Flt-1) and kinase
insert domain-containing receptor (KDR) [33]. Flt-1 and KDR
exhibit tyrosine kinase activity, and both are expressed in the
majority of ECs [33,34]. KDR is a primary mediator of EC pro-
liferation in response to VEGF165. Unlike KDR, Flt-1 is present
in inflammatory cells, and mediates chemotaxis of ECs
[33,34]. Thus, we sought to investigate whether sFasL regu-
lates the expression of VEGF receptors or their signaling path-
ways in ECs. Our results show that sFasL failed to inhibit the
mRNA and protein expression of Flt and KDR expression, as
determined by reverse transcription PCR and Western blot
analysis, respectively (data not shown). However, the
VEGF165-induced expression of phospho-Akt (pAkt), one of
the downstream targets for Flt signaling [35], was dose-
dependently inhibited with sFasL treatment, whereas phos-
pho-extracellular signal-regulated kinase (pERK) activity,
which is critical for EC proliferation [35], remained unchanged
(Figure 5). Taken together, these data suggest that sFasL may
inhibit migration and chemotaxis of ECs by blocking VEGF165-
induced upregulation of pAkt activity.
Figure 3
Soluble Fas ligand (sFasL) does not affect the survival, proliferation and  tube formation of endothelial cells (ECs) Soluble Fas ligand (sFasL) does not affect the survival, proliferation and 
tube formation of endothelial cells (ECs). (a,b) No effect of sFasL on 
the survival (a) and proliferation (b) of ECs. The ECs were incubated for 
24 hours in DMEM supplemented with 1% FCS, and were treated with 
various concentrations of sFasL (1 to 100 ng/ml) in the absence or 
presence of vascular endothelial growth factor (VEGF)165 (10 ng/ml). 
The viability and proliferation of ECs were determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and [3H]-
thymidine incorporation assays, respectively. Data are expressed as the 
mean ± standard deviation (SD) of three independent experiments. (c) 
No effect of sFasL on tube formation by ECs. The ECs were plated on 
Matrigel matrices with VEGF165 (20 ng/ml) in the presence of various 
concentrations (10 to 1,000 ng/ml) of sFasL or soluble CD40 ligand 
(sCD40L) for 48 hours. The total length of the tube network was calcu-
lated using Image-Pro Plus software. Data are representative of three 
independent experiments with similar results, presented as the mean ± 
SD.Arthritis Research & Therapy    Vol 9 No 2    Kim et al.
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sFasL inhibits angiogenesis in vivo
We finally attempted to determine whether sFasL blocks
VEGF165-induced neovascularization in vivo. The in vivo
exposed Matrigel mixtures containing VEGF165 (500 ng/ml)
were colored orange to red, whereas the gels containing
VEGF165 plus sFasL (100 ng/ml) retained their original white
to amber coloring (Figure 6a). In an attempt to quantify the
angiogenesis in these samples, we measured the hemoglobin
contents of the Matrigel mixture gels. The mean hemoglobin
content of the VEGF165-treated Matrigels (n = 8) was 8.30 ±
3.52 g/dl, whereas that of the VEGF165 plus sFasL-treated
Matrigels (n = 8) was 1.20 ± 0.26 g/dl (P < 0.001) (Figure
6b). The stained sections indicate that Matrigels containing
VEGF165 had produced more vessels in the gels than had the
Matrigel containing the VEGF165 plus sFasL (Figure 6c). These
new vessels were filled with an abundance of intact red blood
cells, indicating the formation of a functional vasculature within
the Matrigels. These results appear to suggest that sFasL has
potent anti-angiogenic activity in vivo as well as in vitro.
Discussion
FasL is a type II membrane protein of approximately 280 amino
acids that belongs to the TNF/nerve growth factor family,
which includes TNF, lymphotoxin, CD40L, and TRAIL. FasL
induces apoptotic death in cells expressing its receptor, Fas
[17,35]. FasL undergoes proteolytic cleavage in its extracellu-
lar domains, resulting in the release of sFasL [22]. In general,
sFasL is less potent at inducing apoptosis than membrane-
bound Fas, as shown in a variety of cell types [24,25,36]. Ele-
vated levels of sFasL are found in sera from patients with
atherosclerosis [37], leukemia [38], and acute graft-versus
host disease [39]. The concentration of sFasL in the synovial
fluid is higher in patients with severe RA than in those with mild
RA or OA [27]. Moreover, local injection of sFasL into the
affected joints suppresses experimental arthritis in rats [40],
suggesting it has therapeutic potential in RA.
Angiogenesis has been considered a critical step in the pro-
gression of chronic arthritis, as well as an early determinant in
the development of RA [41]. In this study, we first identified a
Figure 4
Soluble Fas ligand (sFasL) strongly inhibits migration and chemotaxis of endothelial cells (ECs) Soluble Fas ligand (sFasL) strongly inhibits migration and chemotaxis of endothelial cells (ECs). (a) Inhibition of wounding migration of ECs by 
sFasL. Confluent ECs were wounded with the tip of a micropipette, and incubated further in M199 containing 1% FCS with vascular endothelial 
growth factor (VEGF)165 (20 ng/ml) in the absence or presence of sFasL (50 ng/ml). After 12 hours, the cells migrating beyond the reference line 
were photographed (at ×50 magnification) and counted. A representative of three independent experiments is shown. (b) sFasL suppresses the 
chemotaxis of ECs induced by VEGF165. The ECs were placed in the upper wells of the chemotaxis chamber with various concentrations (0.1 to 
100 ng/ml) of soluble CD40 ligand (sCD40L) or sFasL in the presence of VEGF (10 ng/ml) added in the lower wells. The number of cells that had 
migrated to the lower surface of the membrane was counted after hematoxylin and eosin staining. Data are representative of three independent 
experiments, presented as the mean ± standard deviation. †P < 0.01 versus the VEGF165-stimulated cells without sFasL.Available online http://arthritis-research.com/content/9/2/R42
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novel mechanism for anti-angiogenesis in RA involving sFasL.
sFasL decreased VEGF165 production from RA FLSs by induc-
ing apoptosis in vitro. The apoptotic action of sFasL seems to
be specific to RA FLSs because it minimally affected the via-
bility of OA FLSs, which is consistent with the previous finding
that OA FLSs are less sensitive to Fas-mediated apoptosis
[42]. In addition, sFasL drastically suppressed VEGF165-
induced migration and chemotaxis of ECs in vitro and also
blocked neovascularization in vivo, although it did not alter the
proliferation and tube formation of ECs, indicating that sFasL
displays anti-angiogenic activity through at least two different
mechanisms: induction of Fas-mediated cell death of
VEGF165-producing cells; and apoptosis-independent inhibi-
tion of EC migration and chemotaxis. These data, together
with earlier reports [15,40], suggest that administration of
sFasL could be effective in treating several angiogenesis-
dependent diseases, such as cancer and chronic inflammatory
diseases, explaining how sFasL protects against the develop-
ment of experimental arthritis.
RA FLSs are susceptible to anti-Fas IgM and undergo apopto-
sis  in vitro [43,44]. By contrast, apoptotic cells are rarely
observed in the RA synovium in vivo [43]. The effect of FasL
on apoptosis of ECs is also still controversial; although some
studies report that ECs are sensitive to FasL-induced apopto-
sis [45,46], others report the contrary [47,48]. In our experi-
ments, sFasL was able to induce the apoptosis of RA FLSs
and ECs in a culture condition without FCS (Figure 2b; data
Figure 5
Inhibition of vascular endothelial growth factor (VEGF)165-induced  phsospho-Akt (pAkt) activity by soluble Fas ligand (sFasL) Inhibition of vascular endothelial growth factor (VEGF)165-induced 
phsospho-Akt (pAkt) activity by soluble Fas ligand (sFasL). Endothelial 
cells (ECs) were incubated with various concentrations of sFasL (1 to 
50 ng/ml) in the presence of VEGF165 (20 ng/ml) for 10 minutes. The 
pAkt and phospho-extracellular signal-regulated kinase (pERK) expres-
sion levels in the ECs were determined by western blot analysis. The 
data are a representative result of three independent experiments, and 
are expressed as the mean (± standard deviation) optical density ratio 
[pAkt/β-actin]. *P < 0.05 versus the VEGF165-stimulated cells without 
sFasL.
Figure 6
Effect of soluble Fas ligand (sFasL) on neovascularization in vivo Effect of soluble Fas ligand (sFasL) on neovascularization in vivo. 
Matrigel containing vascular endothelial growth factor (VEGF)165 and 
heparin were injected subcutaneously with or without sFasL (100 ng/
ml) into the abdomen of C57BL/6 mice. After 14 days, the mice were 
sacrificed and the Matrigel plugs were excised and fixed. (a) Repre-
sentative Matrigel plugs containing PBS (none), VEGF165 (500 ng/ml), 
or VEGF165 (500 ng/ml) plus sFasL (100 ng/ml). (b) Quantification of 
new vessel formation via measurements of the hemoglobin (Hb) con-
tent within the Matrigel is shown. Eight mice were used for each group. 
Data represent the mean ± standard deviation, and similar results were 
obtained with two different experiments. *P < 0.001 versus the Hb con-
tent of the Matrigel containing VEGF165. (c) Representative photograph 
of the gels shown in cross-section and stained with hematoxylin and 
eosin. Original magnification (×100).Arthritis Research & Therapy    Vol 9 No 2    Kim et al.
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not shown). However, when 1% FCS was added to the
medium, sFasL-mediated cell death was partially inhibited in
the cultured FLSs or did not occur in ECs (Figures 2b and 3a),
indicating that the apoptotic action of sFasL on VEGF-secret-
ing cells, such as FLSs, was hampered by growth factors.
Recently, we have demonstrated that VEGF165 protects FLSs
from apoptotic death by regulating Bcl-2 expression and Bax
translocation [49]. Therefore, it seems unlikely that sFasL
greatly elicits apoptosis of FLSs and ECs in the joints with high
levels of VEGF165 or other growth factors. Instead, a mecha-
nism by which sFasL induces anti-angiogenesis by blocking
migration and chemotaxis of ECs may be more relevant in this
specific condition.
Fas ligation activates a pro-inflammatory program in some cell
types independently of apoptotic responses [50-52]. For
example, Fas stimulation increased expression of IκBα, matrix
metalloproteinases and chemokines, and Fas-activated RA
FLSs displayed increased chemotactic activity for monocytic
cells [50]. In our study, Fas ligation by sFasL did not affect the
production of chemokines, such as IL-8 and monocyte chem-
oattractant protein-1, by ECs (data not shown), suggesting
that Fas ligation does not trigger chemotactic signals for ECs.
On the contrary, sFasL treatment blocked the migration and
chemotaxis of ECs induced by VEGF165 (Figure 4). Moreover,
sFasL strongly inhibited VEGF165-induced pAkt activity, but
not pERK activity, in ECs (Figure 5). It is unclear how sFasL
regulates VEGF165-induced pAkt activity and then suppresses
the chemotaxis and migration of ECs. Activation of the phos-
phatidylinositol 3-kinase/protein kinase Akt pathway mediates
nitric oxide-induced EC migration and angiogenesis [53].
Conversely, inhibition of the Akt pathway results in anti-ang-
iogenic effects through the inhibition of EC migration in an
apoptosis-independent manner [54,55]. Given that the activi-
ties of Flt-1 and its downstream target pAkt are critical to
VEGF165 signaling for chemotaxis [53,54], the anti-migratory
action of sFasL may be mediated by blocking VEGF165-
induced upregulation of pAkt activity. Further study is required
to determine the molecular mechanisms for sFasL regulation
of pAkt activity linked to chemotaxis control.
Conclusion
We demonstrate here that FasL showed anti-angiogenic activ-
ity not only by inducing apoptosis of VEGF-producing cells but
also by blocking VEGF-induced migration of ECs, independ-
ent of Fas-mediated apoptosis. Our data suggest that sFasL
may be effective in the treatment of RA, and could be applica-
ble to the modulation of various chronic VEGF-dependent
inflammatory diseases.
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